A Phase 2 interventional study of Anifrolumab and Placebo in Systemic Lupus Erythematosus, sponsored by AstraZeneca. Completed at 14 sites in 4 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2023-01-12.
Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies testing anifrolumab in Lupus Erythematosus, Systemic — 9 open to participants now, 11 under way, 6 of them phase 3. anifrolumab · Lupus Erythematosus, Systemic.
Among the 20 studies testing anifrolumab in Lupus Erythematosus, Systemic, this one is the 14th largest by enrollment, is the only one that started in 2017, is one of 6 in phase 2, and was the 6th registered.
1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.
Browse Lupus Erythematosus, Systemic studies →9 of the 20 studies testing anifrolumab in Lupus Erythematosus, Systemic are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in Australia, Belgium, Chile and 7 more countries
Ages 5–17
AstraZeneca · Sites in United States, Argentina, Australia and 32 more countries
Ages 5–80
AstraZeneca · Sites in China
Ages 18–70
AstraZeneca · Sites in United States, Canada, France and 6 more countries
Ages 18–70
AstraZeneca · Sites in United States
Ages 18–130 · Women only
By country, each count listing its studies:
anifrolumab: first FDA approval 2021 (SAPHNELO), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →
Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 93 (33%) set no upper age limit and 161 (57%) stop at 75 or younger; 54 take children under 18; 33 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 1 started in 2017.
This study's enrollment of 36 is below the median of 52 across 878 interventional studies indexed under Lupus Erythematosus, Systemic.
Median enrollment 159 across the 20 interventional studies. Of the 8 that completed or were terminated, 7 (88%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 20 have an industry lead sponsor. The 5 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
46 studies in Lupus Erythematosus, Systemic by AstraZeneca: 19 open now, 25 under way, 6 of them phase 3. Of 20 finished, 11 (55%) have results posted.
Among the 46 studies in Lupus Erythematosus, Systemic by AstraZeneca, this one is the 20th largest by enrollment of the 26 interventional ones that give a count, is one of 2 that started in 2017, is one of 9 in phase 2, and was the 11th registered.
AstraZeneca’s Lupus Erythematosus, Systemic studies by the year they started, since 2008.
4 of the studies testing anifrolumab in Lupus Erythematosus, Systemic that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05138133Phase 3AstraZenecaPhase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis | 2027-02-23 |
| NCT05440422National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)The Role of Anifrolumab in Improving Markers of Vascular Risk in Patients With Systemic Lupus Erythematosus (SLE) - IFN-CVD | 2027-08-01 |
| NCT06594068AstraZenecaProspective Registry Investigating Maternal, Infant, and Lactation Outcomes in Anifrolumab Users | 2027-08-31 |
| NCT07913919University of CambridgeEffect of Anifrolumab on Arterial Inflammation in Systemic Lupus Erythematosus Study | 2027-09-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 20 studies testing anifrolumab in Lupus Erythematosus, Systemic, from their registry updates:
Among AstraZeneca’s 46 in Lupus Erythematosus, Systemic:
This tab as a report to print or save as PDF → With an account.
This study will be conducted to characterize pharmacokinetics, pharmacodynamics, safety, and tolerability of anifrolumab given via the subcutaneous (SC) route of administration in adult Systemic Lupus Erythematosus (SLE) subjects with a type I Interferon (IFN) test high result and active skin manifestations while receiving Standard of Care (SOC) treatment. In addition, the efficacy of anifrolumab on SLE skin manifestations will be characterized.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Diagnosis of paediatric or adult SLE for > 24 weeks and fulfilling ≥4 of the 11 American College of Rheumatology (ACR) classification criteria with at least one being:
Currently receiving at least 1 of the following for treatment of SLE:
Exclusion Criteria:
History of cancer, apart from:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
1ml, once every second week, one subcutaneous injection as added to stand of care, from week 0 to week 50
Drug: Anifrolumab
1ml, once every second week, one subcutaneous injection added to stand of care, from week 0 to week 50
Drug: Placebo
2×1ml, once every second week, two subcutaneous injections as added to stand of care, from week 0 to week 50
Drug: Anifrolumab
2×1ml , once every second week, two subcutaneous injections as added to stand of care, from week 0 to week 50
Drug: Placebo
subcutaneous administration every 2 weeks from week 0 to week 50
subcutaneous administration every two weeks from week 0 to week 50
Maximum Concentration of Anifrolumab in Serum After First Dose
Maximum concentration (Cmax) of anifrolumab is based on sample collected 5 to 8 days after the first dose of strudy treatment.
Time frame: Week 0
Steady-state Serum Trough (Predose) Concentration (Ctrough) of Anifrolumab
Steady-state serum through concentration (Ctrough) is based on sample collected at Week 12 prior to dosing of study treatment (predose).
Time frame: Week 12
21-gene Type 1 IFN Signature Score (Fold-change)
21-gene type I IFN signature score (fold change) is based on samples collected both at baseline and Week 12 prior to dosing of study treatment. Levels of 21-gene type I IFN pharmacodynamics signature is derived as relative to a pooled normal control.
Time frame: Week 12
21-gene Type 1 IFN Neutralization Ratio (Percent Suppression of Fold Change)
21-gene type I IFN signature score (fold change) is based on samples collected both at baseline and Week 12 prior to dosing of study treatment. For each individual participant and assessment, the level of 21-gene type I IFN pharmacodynamics signature is derived as relative to a pooled normal control, as the median of 100-(((baseline-Week 12)/baseline)\*100) for the 21 genes. At a population level, the results are presented as mean the above.
Time frame: Week 12
Number of Participants With Antidrug Antibody (ADA)
Post-baseline ADA incidence based on the number of participants with Antidrug antibody (ADA)
Time frame: Baseline to Week 52
Number of Participants With Neutralizing Antibodies (nAb)
Incidence of detectable nAb in post-baseline ADA positive participants.
Time frame: Baseline to Week 52
Number AEs (Adverse Events) and SAEs (Serious Adverse Events), Including Adverse Events of Special Interest (AESI)
Number of participants with any AEs (Adverse events), any SAEs (serious adverse events), and any adverse events of special interest (AESI) are summarized. More details are reported in the Adverse Events section.
Time frame: Baseline to Week 52
Change From Baseline for Vital Signs
Change from baseline for vital signs.
Time frame: Baseline to Week 60
Change From Baseline for Physical Examination
Physical examination is reported as change from baseline in body weight.
Time frame: Baseline to Week 60
Change From Baseline for 12-lead ECG
The 12-lead ECG measurements were assessed by the investigators, and reported as normal, abnormal (not clinically significant \[NCS\]), abnormal (clinically significant \[CS\]), or not done.
Time frame: Baseline to Week 52
Value of Haemoglobin Blood Test to Detect Change From Baseline
Change from baseline in haemoglobin blood tests are reported.
Time frame: Baseline to Week 60
Value of Haematology Blood Tests to Detect Change From Baseline
Change from baseline in haematology blood tests (leucocytes \[particle concentration\], platelets \[particle concentration\]) are reported.
Time frame: Baseline to Week 60
Value of Protein-creatinine Urinalysis Test to Detect Change From Baseline
Change from baseline in protein-creatinine ratio urinalysis tests are reported.
Time frame: Baseline to Week 60
Value of Total Protein Urinalysis Test to Detect Change From Baseline
Change from baseline in total protein urinalysis tests are reported.
Time frame: Baseline to Week 60
Value of Clinical Chemistry Blood Tests to Detect Change From Baseline (Serum)
Change from baseline in clinical chemistry blood tests (Alanine Aminotransferase, Aspartate Aminotransferase) are reported.
Time frame: Baseline to Week 60
Value of Creatinine Clinical Chemistry Blood Tests to Detect Change From Baseline (Serum)
Change from baseline in clinical creatinine chemistry blood tests (serum) are reported.
Time frame: Baseline to Week 60
Value of Inflammatory Marker Panel Blood Tests to Detect Change From Baseline
Change from baseline in the Erythrocyte Sedimentation Rate (ESR) inflammatory marker is reported.
Time frame: Baseline to Week 60
Value of Autoantibody Blood Panel Blood Tests to Detect Change From Baseline
Change from baseline in Anti-Double Stranded DNA IgG (anti-dsDNA) is reported.
Time frame: Baseline to Week 60
Number of Participants With Positive Hepatitis B Core Antibody Post-baseline.
Change from screening in Hepatitis B core antibody was monitored during the study for participants tested positive at screening.
Time frame: Baseline to Week 60
Participants type I Interferon (IFN) test-high Systemic Lupus Erythematosus (SLE) subjects with active skin manifestations while receiving Standard of Care (SOC) treatment were eligible for the study.
| Milestone | Anifrolumab - Lower Dose | Anifrolumab - Higher Dose | Placebo Comparator |
|---|---|---|---|
| Started | 14 | 13 | 9 |
| Completed | 11 | 11 | 9 |
| Not completed | 3 | 2 | 0 |
| Withdrew: Withdrawal by subject | 1 | 1 | 0 |
| Withdrew: Adverse event | 1 | 1 | 0 |
| Withdrew: Protocol violation | 1 | 0 | 0 |
Maximum concentration (Cmax) of anifrolumab is based on sample collected 5 to 8 days after the first dose of strudy treatment.
| mcg/mL | Anifrolumab - Lower Dose | Anifrolumab - Higher Dose |
|---|---|---|
| Maximum Concentration of Anifrolumab in Serum After First Dose | 14.058 ± 49.8151 | 28.115 ± 74.4916 |
Steady-state serum through concentration (Ctrough) is based on sample collected at Week 12 prior to dosing of study treatment (predose).
| mcg/mL | Anifrolumab - Lower Dose | Anifrolumab - Higher Dose |
|---|---|---|
| Steady-state Serum Trough (Predose) Concentration (Ctrough) of Anifrolumab | 15.618 ± 81.3595 | 16.926 ± 9205.6677 |
21-gene type I IFN signature score (fold change) is based on samples collected both at baseline and Week 12 prior to dosing of study treatment. Levels of 21-gene type I IFN pharmacodynamics signature is derived as relative to a pooled normal control.
| fold change | Anifrolumab - Lower Dose | Anifrolumab - Higher Dose | Placebo Comparator |
|---|---|---|---|
| 21-gene Type 1 IFN Signature Score (Fold-change) | 3.2 ± 3.69 | 3.5 ± 5.73 | 14.3 ± 6.68 |
21-gene type I IFN signature score (fold change) is based on samples collected both at baseline and Week 12 prior to dosing of study treatment. For each individual participant and assessment, the level of 21-gene type I IFN pharmacodynamics signature is derived as relative to a pooled normal control, as the median of 100-(((baseline-Week 12)/baseline)\*100) for the 21 genes. At a population level, the results are presented as mean the above.
| percentage neutralization | Anifrolumab - Lower Dose | Anifrolumab - Higher Dose | Placebo Comparator |
|---|---|---|---|
| 21-gene Type 1 IFN Neutralization Ratio (Percent Suppression of Fold Change) | 77.5 ± 24.16 | 80.5 ± 36.65 | 15.1 ± 49.63 |
Post-baseline ADA incidence based on the number of participants with Antidrug antibody (ADA)
| Participants | Anifrolumab - Lower Dose | Anifrolumab - Higher Dose | Placebo Comparator |
|---|---|---|---|
| Number of Participants With Antidrug Antibody (ADA) | 1 | 1 | 0 |
Incidence of detectable nAb in post-baseline ADA positive participants.
| Participants | Anifrolumab - Lower Dose | Anifrolumab - Higher Dose | Placebo Comparator |
|---|---|---|---|
| Number of Participants With Neutralizing Antibodies (nAb) | 0 | 0 | 0 |
Number of participants with any AEs (Adverse events), any SAEs (serious adverse events), and any adverse events of special interest (AESI) are summarized. More details are reported in the Adverse Events section.
| Participants | Anifrolumab - Lower Dose | Anifrolumab - Higher Dose | Placebo Comparator |
|---|---|---|---|
| Any adverse event | 12 | 11 | 7 |
| Any serious adverse event | 4 | 2 | 0 |
| Any adverse event of special interest | 5 | 1 | 1 |
Change from baseline for vital signs.
| mmHg | Anifrolumab - Lower Dose | Anifrolumab - Higher Dose | Placebo Comparator to Lower Dose | Placebo Comparator to Higher Dose |
|---|---|---|---|---|
| Systolic Blood Pressure (mmHg) - Week 12 | -4.1 ± 12.08 | 3 ± 6.63 | -5.8 ± 13.99 | 7.3 ± 8.96 |
| Systolic Blood Pressure (mmHg) - Week 52 | 2.1 ± 10.96 | -1.7 ± 12.96 | 3.4 ± 8.53 | 12.5 ± 19.36 |
| Systolic Blood Pressure (mmHg) - Week 60 | 4.1 ± 19.70 | -2.8 ± 14.91 | 12.2 ± 8.61 | 4.5 ± 7.14 |
| Diastolic Blood Pressure (mmHg) - Week 12 | -2.0 ± 10.02 | 2.4 ± 6.71 | -3.8 ± 6.50 | 4.3 ± 4.35 |
| Diastolic Blood Pressure (mmHg) - Week 52 | 0.1 ± 6.87 | 2.9 ± 7.54 | -0.4 ± 7.13 | 6.8 ± 5.38 |
| Diastolic Blood Pressure (mmHg) - Week 60 | 3.6 ± 12.23 | -0.8 ± 6.86 | -1.0 ± 8.22 | 8.8 ± 6.29 |
Physical examination is reported as change from baseline in body weight.
| kilograms | Anifrolumab - Lower Dose | Anifrolumab - Higher Dose | Placebo Comparator to Lower Dose | Placebo Comparator to Higher Dose |
|---|---|---|---|---|
| Week 12 | -1.81 ± 2.674 | 1.37 ± 3.113 | 0.7 ± 1.889 | 0.98 ± 2.904 |
| Week 52 | -2.83 ± 4.683 | 2.52 ± 6.495 | 0.30 ± 3.338 | 3.90 ± 5.608 |
| Week 60 | -1.81 ± 3.858 | 2.93 ± 6.463 | 1.06 ± 4.020 | 3.60 ± 5.300 |
The 12-lead ECG measurements were assessed by the investigators, and reported as normal, abnormal (not clinically significant \[NCS\]), abnormal (clinically significant \[CS\]), or not done.
| Participants | Anifrolumab - Lower Dose | Anifrolumab - Higher Dose | Placebo Comparator to Lower Dose | Placebo Comparator to Higher Dose |
|---|---|---|---|---|
| Normal baseline - Normal Week 52 | 7 | 10 | 5 | 3 |
| Normal baseline - Abnormal (NCS) Week 52 | 1 | 1 | 0 | 0 |
| Normal baseline - not done Week 52 | 1 | 2 | 0 | 0 |
| Abnormal (NCS) baseline - Normal Week 52 | 2 | 0 | 0 | 1 |
| Abnormal (NCS) baseline - Abnormal (NCS) Week 52 | 1 | 0 | 0 | 0 |
| Abnormal (NCS) baseline - not done Week 52 | 2 | 0 | 0 | 0 |
| Not done baseline - Normal Week 52 | 0 | 0 | 0 | 0 |
| Not done baseline - Abnormal (NCS) Week 52 | 0 | 0 | 0 | 0 |
| Not done baseline - Not done Week 52 | 0 | 0 | 0 | 0 |
| Normal baseline - Abnormal (CS) Week 52 | 0 | 0 | 0 | 0 |
| Abnormal (NCS) baseline - Abnormal (CS) Week 52 | 0 | 0 | 0 | 0 |
| Not done baseline - Abnormal (CS) Week 52 | 0 | 0 | 0 | 0 |
| Abnormal (CS) baseline - Normal Week 52 | 0 | 0 | 0 | 0 |
| Abnormal (CS) baseline - Abnormal (CS) Week 52 | 0 | 0 | 0 | 0 |
| Abnormal (CS) baseline - Not done Week 52 | 0 | 0 | 0 | 0 |
| Abnormal (CS) baseline - Abnormal (NCS) Week 52 | 0 | 0 | 0 | 0 |
Change from baseline in haemoglobin blood tests are reported.
| g/L | Anifrolumab - Lower Dose | Anifrolumab - Higher Dose | Placebo Comparator to Lower Dose | Placebo Comparator to Higher Dose |
|---|---|---|---|---|
| Haemoglobin - Week 12 | -0.2 ± 9.07 | 0.7 ± 7.4 | -0.5 ± 7.14 | 4.8 ± 5.91 |
| Haemoglobin - Week 52 | -1.1 ± 13.92 | 0.1 ± 11.65 | -4.8 ± 3.83 | 7 ± 5.94 |
| Haemoglobin - Week 60 | 0.8 ± 12.97 | 0 ± 10.43 | -5.4 ± 5.68 | 5.8 ± 6.85 |
Change from baseline in haematology blood tests (leucocytes \[particle concentration\], platelets \[particle concentration\]) are reported.
| 10^9/L | Anifrolumab - Lower Dose | Anifrolumab - Higher Dose | Placebo Comparator to Lower Dose | Placebo Comparator to Higher Dose |
|---|---|---|---|---|
| Leucocytes - Week 12 | 0.491 ± 1.5806 | 3.165 ± 2.2706 | 0.867 ± 1.0999 | 1.96 ± 1.9487 |
| Leucocytes - Week 52 | 1.041 ± 1.5794 | 2.457 ± 2.3891 | 0.236 ± 1.0107 | 0.080 ± 1.4798 |
| Leucocytes - Week 60 | -0.012 ± 1.5489 | 1.474 ± 1.6490 | 0.776 ± 2.1779 | 1.23 ± 1.6687 |
| Platelets - Week 12 | 7.8 ± 65.28 | 45.2 ± 67.41 | 10.3 ± 24.54 | 17.0 ± 42.58 |
| Platelets - Week 52 | 28.0 ± 74.28 | 46.1 ± 74.91 | 6.6 ± 64.24 | -2.0 ± 33.85 |
| Platelets - Week 60 | -19.1 ± 53.48 | 39.0 ± 60.33 | 24.4 ± 65.73 | -2.8 ± 28.43 |
Change from baseline in protein-creatinine ratio urinalysis tests are reported.
| g/g | Anifrolumab - Lower Dose | Anifrolumab - Higher Dose | Placebo Comparator to Lower Dose | Placebo Comparator to Higher Dose |
|---|---|---|---|---|
| Protein/Creatinine - Week 12 | 1.37029 ± 5.186672 | -0.13007 ± 1.123807 | -0.03056 ± 0.056701 | 0.32764 ± 0.337631 |
| Protein/Creatinine - Week 52 | 0.03756 ± 0.135157 | -0.00465 ± 0.183327 | -0.00781 ± 0.047671 | 0.080930 ± 1.581772 |
| Protein/Creatinine - Week 60 | 0.02578 ± 0.119862 | -0.28836 ± 1.185347 | -0.03501 ± 0.061888 | 0.46178 ± 0.899886 |
Change from baseline in total protein urinalysis tests are reported.
| g/L | Anifrolumab - Lower Dose | Anifrolumab - Higher Dose | Placebo Comparator to Lower Dose | Placebo Comparator to Higher Dose |
|---|---|---|---|---|
| Protein, Total - Week 12 | 0.7669 ± 2.71221 | -0.0744 ± 0.76445 | 0 ± 0 | 0.3443 ± 0.34301 |
| Protein, Total - Week 52 | -0.0029 ± 0.08124 | -0.0011 ± 0.33468 | 0 ± 0 | 0.1143 ± 0.24476 |
| Protein, Total - Week 60 | 0.1151 ± 0.12514 | -0.1790 ± 0.83066 | 0.003 ± 0.00671 | 0.3975 ± 0.82602 |
Change from baseline in clinical chemistry blood tests (Alanine Aminotransferase, Aspartate Aminotransferase) are reported.
| ukat/L | Anifrolumab - Lower Dose | Anifrolumab - Higher Dose | Placebo Comparator to Lower Dose | Placebo Comparator to Higher Dose |
|---|---|---|---|---|
| Alanine Aminotransferase - Week 12 | 0.00769 ± 0.147479 | -0.13003 ± 0.431764 | -0.05418 ± 0.045905 | 0.02501 ± 0.134397 |
| Alanine Aminotransferase - Week 52 | -0.06335 ± 0.119642 | -0.05607 ± 0.556152 | -0.06335 ± 0.047735 | 0.04167 ± 0.169182 |
| Alanine Aminotransferase - Week 60 | -0.01297 ± 0.043131 | 0.09446 ± 0.365981 | -0.04334 ± 0.032495 | -0.01667 ± 0.18127 |
| Aspartate Aminotransferase - Week 12 | -0.01154 ± 0.065765 | -0.10502 ± 0.169099 | 0.00417 ± 0.059911 | 0.03334 ± 0.105430 |
| Aspartate Aminotransferase - Week 52 | -0.04834 ± 0.066424 | -0.05304 ± 0.196369 | 0.00333 ± 0.090847 | 0.09169 ± 0.100482 |
| Aspartate Aminotransferase - Week 60 | -0.01111 ± 0.058937 | 0.04816 ± 0.123752 | 0 ± 0.050010 | -0.02501 ± 0.099555 |
Change from baseline in clinical creatinine chemistry blood tests (serum) are reported.
| umol/L | Anifrolumab - Lower Dose | Anifrolumab - Higher Dose | Placebo Comparator to Lower Dose | Placebo Comparator to Higher Dose |
|---|---|---|---|---|
| Creatinine - Week 12 | 4.385 ± 8.5799 | -3.6 ± 11.2467 | 5.5 ± 6.3509 | 5.25 ± 9.8446 |
| Creatinine - Week 52 | 12.2 ± 33.2597 | -7.273 ± 19.5862 | 0.2 ± 13.9714 | 2.5 ± 5.5076 |
| Creatinine - Week 60 | 7.316 ± 8.7449 | -5.556 ± 12.8463 | 5.0 ± 10.4163 | 6.5 ± 12.5033 |
Change from baseline in the Erythrocyte Sedimentation Rate (ESR) inflammatory marker is reported.
| mm | Anifrolumab - Lower Dose | Anifrolumab - Higher Dose | Placebo Comparator |
|---|---|---|---|
| ESR - Week 12 | -3.0 ± 20.37 | -7.2 ± 15.46 | -11.9 ± 15.36 |
| ESR - Week 52 | 5.6 ± 25.58 | -6.7 ± 12.25 | -16.0 ± 10.95 |
| ESR - Week 60 | 14.6 ± 38.77 | -1.0 ± 21.84 | 2.2 ± 22.48 |
Change from baseline in Anti-Double Stranded DNA IgG (anti-dsDNA) is reported.
| IU/mL | Anifrolumab - Lower Dose | Anifrolumab - Higher Dose | Placebo Comparator to Lower Dose | Placebo Comparator to Higher Dose |
|---|---|---|---|---|
| anti-dsDNA - Week 12 | -42.09 ± 256.228 | -84.97 ± 231.489 | -37.0 ± 19.799 | -97.33 ± 151.596 |
| anti-dsDNA - Week 52 | -99.04 ± 288.183 | 8.70 ± 27.308 | -13.0 ± 50.229 | -76.87 ± 127.433 |
| anti-dsDNA - Week 60 | 52.67 ± 144.220 | 16.53 ± 30.528 | -21.33 ± 54.921 | -76.73 ± 141.525 |
Change from screening in Hepatitis B core antibody was monitored during the study for participants tested positive at screening.
No measurements were reported for this outcome.
Collected over 52 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Anifrolumab - Lower Dose | 0/14 (0%) | 4/14 (28.6%) | 12/14 (85.7%) |
| Anifrolumab - Higher Dose | 0/13 (0%) | 2/13 (15.4%) | 11/13 (84.6%) |
| Placebo Comparator | 0/9 (0%) | 0/9 (0%) | 7/9 (77.8%) |
| Event | Anifrolumab - Lower Dose | Anifrolumab - Higher Dose | Placebo Comparator |
|---|---|---|---|
| Systemic Lupus ErythematosusMusculoskeletal and connective tissue disorders | 1/14 | 1/13 | 0/9 |
| Lupus NephritisRenal and urinary disorders | 1/14 | 1/13 | 0/9 |
| Herpes ZosterInfections and infestations | 1/14 | 0/13 | 0/9 |
| Otitis Media AcuteInfections and infestations | 1/14 | 0/13 | 0/9 |
| Transient Ischaemic AttackNervous system disorders | 1/14 | 0/13 | 0/9 |
| Mouth UlcerationGastrointestinal disorders | 1/14 | 0/13 | 0/9 |
| Event | Anifrolumab - Lower Dose | Anifrolumab - Higher Dose | Placebo Comparator |
|---|---|---|---|
| Upper Respiratory Tract InfectionInfections and infestations | 5/14 | 1/13 | 3/9 |
| BronchitisInfections and infestations | 1/14 | 3/13 | 1/9 |
| DiarrhoeaGastrointestinal disorders | 2/14 | 0/13 | 2/9 |
| NasopharyngitisInfections and infestations | 3/14 | 2/13 | 1/9 |
| HeadacheNervous system disorders | 2/14 | 2/13 | 0/9 |
| SciaticaNervous system disorders | 0/14 | 2/13 | 0/9 |
| Herpes ZosterInfections and infestations | 2/14 | 0/13 | 1/9 |
| Back PainMusculoskeletal and connective tissue disorders | 2/14 | 1/13 | 1/9 |
| Abscess LimbInfections and infestations | 0/14 | 0/13 | 1/9 |
| SinusitisInfections and infestations | 0/14 | 0/13 | 1/9 |
Includes all participants randomized into the study who receive at least one dose of investigational product, according to randomized treatment (modified Intention-To-Treat).
| Age, Continuous(years) | Anifrolumab - Lower Dose | Anifrolumab - Higher Dose | Placebo Comparator | Total |
|---|---|---|---|---|
| Mean | 46.3 ± 9.1 | 41.5 ± 9.2 | 47.8 ± 14.2 | 44.9 ± 10.6 |
| Sex: Female, Male(Participants) | Anifrolumab - Lower Dose | Anifrolumab - Higher Dose | Placebo Comparator | Total |
|---|---|---|---|---|
| Female | 12 | 12 | 8 | 32 |
| Male | 2 | 1 | 1 | 4 |
| Ethnicity (NIH/OMB)(Participants) | Anifrolumab - Lower Dose | Anifrolumab - Higher Dose | Placebo Comparator | Total |
|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 14 | 13 | 9 | 36 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Anifrolumab - Lower Dose | Anifrolumab - Higher Dose | Placebo Comparator | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 6 | 2 | 0 | 8 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 |
| White | 8 | 11 | 9 | 28 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Feb 2017 to primary completion in Jan 2018, 11 months.
Results were first posted in Dec 2019, 1 year 10 months after primary completion. A results delay was requested in Sep 2018.
Of 67 industry-sponsored phase 2 interventional studies under Lupus Erythematosus, Systemic, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 48. This study's 11 months is below that.
Counting every sponsor, half of 95 studies reached it within 36 months; a quarter within 27 and three quarters within 56.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Anifrolumab
Lupus Erythematosus, Systemic →